• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Neuropace, Inc. - Common Stock (NQ:NPCE)

    9.940 +0.080 (+0.81%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 158,046
    Open 9.790
    Bid (Size) 8.980 (1)
    Ask (Size) 11.49 (1)
    Prev. Close 9.860
    Today's Range 9.680 - 10.02
    52wk Range 6.030 - 18.98
    Shares Outstanding 24,296,259
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Integer Holdings (ITGR) Shares Plunge 31.4% as Slower New Product Adoption and Revised Guidance Rock Investor Confidence
    New York, NY – October 23, 2025 – Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract manufacturer, experienced a dramatic downturn in its stock performance today, with shares... 
    Via MarketMinute
    Topics Earnings Supply Chain
    NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
    From NeuroPace, Inc.
    Via Business Wire

    Performance

    YTD
    -14.2%
    -14.2%
    1 Month
    -2.0%
    -2.0%
    3 Month
    +10.6%
    +10.6%
    6 Month
    -17.0%
    -17.0%
    1 Year
    +54.1%
    +54.1%

    More News

    Read More
    NeuroPace to Participate in Upcoming Healthcare Conferences
    From NeuroPace, Inc.
    Via Business Wire
    NeuroPace Revenue Jumps 22 Percent in Q2
    Via The Motley Fool
    NeuroPace (NPCE) Q2 2025 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    NeuroPace Reports Record Q2 Revenue
    Via The Motley Fool
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    From Pomerantz LLP
    Via GlobeNewswire
    Earnings Scheduled For August 12, 2025
    Via Benzinga
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    Via ACCESS Newswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    Via ACCESS Newswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    Via ACCESS Newswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    Via ACCESS Newswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    From Pomerantz LLP
    Via GlobeNewswire
    NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    Via ACCESS Newswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, Inc. - NPCE
    From Pomerantz LLP
    Via GlobeNewswire
    Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
    From Pomerantz LLP
    Via GlobeNewswire

    Frequently Asked Questions

    Is Neuropace, Inc. - Common Stock publicly traded?
    Yes, Neuropace, Inc. - Common Stock is publicly traded.
    What exchange does Neuropace, Inc. - Common Stock trade on?
    Neuropace, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Neuropace, Inc. - Common Stock?
    The ticker symbol for Neuropace, Inc. - Common Stock is NPCE on the Nasdaq Stock Market
    What is the current price of Neuropace, Inc. - Common Stock?
    The current price of Neuropace, Inc. - Common Stock is 9.940
    When was Neuropace, Inc. - Common Stock last traded?
    The last trade of Neuropace, Inc. - Common Stock was at 10/31/25 04:00 PM ET
    What is the market capitalization of Neuropace, Inc. - Common Stock?
    The market capitalization of Neuropace, Inc. - Common Stock is 241.50M
    How many shares of Neuropace, Inc. - Common Stock are outstanding?
    Neuropace, Inc. - Common Stock has 242M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.